All relevant data are within the paper.

Introduction {#sec006}
============

Cerebral venous thrombosis is rare thrombotic condition commonly associated with the presence of thrombophilia\[[@pone.0151607.ref001]\]. Prothrombin G20210A is one of the most common thrombophilias associated with venous thrombosis, including cerebral venous thrombosis\[[@pone.0151607.ref002]\]. In patients with deep vein thrombosis or pulmonary embolism the prevalence of prothrombin G20210A is highly dependent on the country of origin or ethnicity \[[@pone.0151607.ref003]--[@pone.0151607.ref007]\] but this variation has not been evaluated in patients with cerebral venous thrombosis. To address this issue, we examined the prevalence and geographical variation of carriers of the prothrombin G20210A in patients with cerebral vein or cortical vein thrombosis.

Methods {#sec007}
=======

We conducted a systematic review of electronic databases including MEDLINE and EMBASE to assess the prevalence of Prothrombin G20210A in patients with cerebral vein thrombosis ([S1 Text](#pone.0151607.s003){ref-type="supplementary-material"}). The timeframe of the search was from Jan 1995 to February 2015 and was designed with the support of a librarian from the Ottawa Hospital Health Services. The search was supplemented by hand-search of relevant articles, abstract books from international meetings and published reviews.

Study Selection {#sec008}
---------------

Case control studies were included if they reported the prevalence of prothrombin G20210A in patients with objectively confirmed cerebral vein or cortical vein thrombosis. All potentially relevant articles were reviewed in full length to ensure that they satisfied the inclusion criteria: 1) enrolment of non-paediatric patients with cerebral vein or cortical vein thrombosis; 2) the study reported the diagnostic test used to confirm the diagnosis (including digital subtraction angiography, MRI, CT angiography or autopsy); 3) Prothrombin G20210A genotyping was available for all participants; 4) the numbers of cases and controls with and without prothrombin G20210A were provided in the article. Studies were excluded if their subjects did not receive objective testing for the prothrombin G20210A mutation, included a paediatric population or included patients in which the diagnostic methods was not reported or patient with self-reported cerebral venous thrombosis.

Data Extraction and Quality Assessment {#sec009}
--------------------------------------

Two reviewers (J.G. and E.G.) independently assessed the eligibility of all articles identified in the initial search strategy and used the Newcastle--Ottawa Quality Assessment Scale for Observational Studies to assess the methodological quality of the selected studies. A third reviewer adjudicated all discrepancies if needed (A.B.)

Outcome Measure {#sec010}
---------------

The primary outcome measure was the odds ratio (OR) for the prevalence of prothrombin G20210A patients with cerebral vein or cortical vein thrombosis as compared with healthy controls. We also aimed to analyze the prevalence of prothrombin G20210A mutation across different countries, if two or more studies were available.

Data Synthesis and Analysis {#sec011}
---------------------------

The meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement ([S1](#pone.0151607.s001){ref-type="supplementary-material"} and [S2](#pone.0151607.s002){ref-type="supplementary-material"} Tables presents the meta-analysis of genetic association studies checklist). The random-effects model OR was used as the outcome measure, along with the corresponding 95% confidence intervals (CIs). The I^2^ statistic was used to quantify heterogeneity among the pooled estimates across studies. An I^2^ value less than 25% was considered low-level heterogeneity, 25% to 50% as moderate-level, and greater than 50% as high-level. Homozygote and heterozygote carriers of prothrombin G20210A were analyzed as one group due to the rarity of homozygote carriers. A funnel plot and test for bias using the Harbord and Egger test\[[@pone.0151607.ref008]\]. We also added a L\'Abbé plot which is useful for exploring heterogeneity and identifying outlying trials in a meta-analysis\[[@pone.0151607.ref009]\]. The statistical analysis and graphs were performed using MedCalc Statistical Software version 12.7.7 (MedCalc Software, Ostend, Belgium; <http://www.medcalc.org>; 2013) and the bias analysis was performed with STATS direct (StatsDirect Ltd. StatsDirect statistical software. <http://www.statsdirect.com>. England: StatsDirect Ltd. 2013).

Results {#sec012}
=======

As shown in [fig 1](#pone.0151607.g001){ref-type="fig"} our initial electronic search identified 238 relevant abstracts (after removal of duplicates). One hundred and ninety five were considered non-relevant to the search and excluded. Of the 43 that were selected for full text review 21\[[@pone.0151607.ref010]--[@pone.0151607.ref030]\]were included in this review, 19\[[@pone.0151607.ref010]--[@pone.0151607.ref012],[@pone.0151607.ref014],[@pone.0151607.ref016]--[@pone.0151607.ref025],[@pone.0151607.ref027]--[@pone.0151607.ref031]\]of which were used for the primary analysis (in [Table 1](#pone.0151607.t001){ref-type="table"} we present the studies characteristics and in [Table 2](#pone.0151607.t002){ref-type="table"} their quality assessment); 22 were excluded for the reasons described in [Fig 1](#pone.0151607.g001){ref-type="fig"}. Two studies were excluded from the primary analysis as they did not report the method used for the diagnosis of cerebral venous thrombosis\[[@pone.0151607.ref013],[@pone.0151607.ref026]\]. Five of the studies were conducted in Italy\[[@pone.0151607.ref017],[@pone.0151607.ref021],[@pone.0151607.ref027],[@pone.0151607.ref029],[@pone.0151607.ref031]\], three in Brazil\[[@pone.0151607.ref018],[@pone.0151607.ref025],[@pone.0151607.ref028]\], three in Germany\[[@pone.0151607.ref010],[@pone.0151607.ref020],[@pone.0151607.ref024]\], two in Iran\[[@pone.0151607.ref016],[@pone.0151607.ref023]\], one in France\[[@pone.0151607.ref019]\], one in India\[[@pone.0151607.ref032]\],one in Netherlands\[[@pone.0151607.ref030]\]one in Switzerland\[[@pone.0151607.ref011]\], one in Tunisia\[[@pone.0151607.ref014]\] and one in the United Kingdom\[[@pone.0151607.ref012]\].

10.1371/journal.pone.0151607.t001

###### Characteristics of the studies included.

![](pone.0151607.t001){#pone.0151607.t001g}

  Study                                              Year   Country       Diagnostic method                         N CVT   N Controls   Matched?                                                                  Hardy-Weinberg equilibrium assessed?   \% pregnancy CVT   \% OCP CVT   \% Female with CVT
  -------------------------------------------------- ------ ------------- ----------------------------------------- ------- ------------ ------------------------------------------------------------------------- -------------------------------------- ------------------ ------------ --------------------
  **Ashjazadeh**\[[@pone.0151607.ref016]\]           2012   Iran          MRI and MRV                               57      50           Yes, age/gender/ethnicity                                                 No                                     7                  47           66
  **Ben Salem-Berrabah**\[[@pone.0151607.ref014]\]   2012   Tunisia       CT scan, MRI/MRV or autopsy               26      197          No                                                                        Yes, in equilibrium                    .                  .            80
  **Bombeli**\[[@pone.0151607.ref011]\]              2002   Switzerland   CT scan, MRI/MRV or autopsy               51      120          No                                                                        No                                     .                  3.2          76.5
  **Boncoraglio**\[[@pone.0151607.ref017]\]          2004   Italy         Angiography, CT or MRI                    26      100          No, healthy hospital workers                                              No                                     .                  42           73
  **Colaizo**\[[@pone.0151607.ref029]\]              2007   Italy         Digital angiography, CT or MRI            45      286          sex, age and social status                                                Yes                                    NA                 NA           69%
  **Gadelha**\[[@pone.0151607.ref018]\]              2005   Brazil        Angiography or MRI                        21      217          Age/racial background, no history of thrombosis or genetic relationship   No                                     .                  85%          84
  **Hillier**\[[@pone.0151607.ref012]\]              1998   UK            Digital angiography, CT, autopsy or MRI   15      300          No                                                                        No                                     .                  38           70
  **Koopman**\[[@pone.0151607.ref030]\]              2009   Netherlands   Digital angiography, CT, surgery or MRI   19      19           Age and Sex                                                               No                                     20%                60%          79%
  **Le Cam-Duchez**\[[@pone.0151607.ref019]\]        2005   France        Angiography or MRI                        26      84           Age and sex                                                               No                                     9                  44           69
  **Lichy**\[[@pone.0151607.ref020]\]                2005   Germany       MRI and/or angiography                    77      203          No                                                                        No                                     11.30%             43%          78%
  **Madonna**\[[@pone.0151607.ref021]\]              2000   Italy         MRI and/or angiography                    10      254          Sex and age                                                               No                                     .                  33           60%
  **Martinelli** \[[@pone.0151607.ref031]\]          2003   Italy         MRI, CT and/or angiography                121     242          Sex, age, geographic origin, and level of education                       No                                     NA                 96%          74%
  **Nagaraja**\[[@pone.0151607.ref032]\]             2007   India         MRI/MRV                                   96      103          Age                                                                       No                                     100                0            100
  **Rahimi**\[[@pone.0151607.ref023]\]               2010   Iran          MRI                                       24      100          Age/ gender; Kurdish descent                                              No                                     .                  .            70%
  **Reuner**\[[@pone.0151607.ref010]\]               1998   Germany       MRI and/or angiography                    45      354          No                                                                        No                                     10                 85           75%
  **Ringelstein**\[[@pone.0151607.ref024]\]          2012   Germany       MRI and/or angiography                    136     1054         No, but same ethnicity                                                    Not done for prothrombin gene          .                  NR           34
  **Rodrigues**\[[@pone.0151607.ref025]\]            2004   Brazil        MRI and/or angiography                    42      134          No                                                                        No                                     20                 60           67
  **Ventura**\[[@pone.0151607.ref027]\]              2004   Italy         MRI, CT and/or angiography                30      40           Age/gender                                                                No                                                        9            53
  **Voetsch**\[[@pone.0151607.ref028]\]              2000   Brazil        MRI, CT and/or angiography                14      225          Age/gender                                                                No                                     .                  .            71
  **Excluded from main analysis**                                                                                                                                                                                                                                                         
  **Tufano**\[[@pone.0151607.ref026]\]               2014   Italy         Not reported                              56      184          Age/gender same ethnicity                                                                                        NR                 53.7         73%
  **Margaglione**\[[@pone.0151607.ref013]\]          2001   Italy         Not reported                              28      1304         No                                                                                                               .                  .            .

CVT: Cerebral venous thrombosis; OCP: Oral contraception; CT: computerized axial tomography; MRI/MRV: Magnetic resonance imaging (MRI) or magnetic resonance venography; Angiography: digital subtraction angiography

10.1371/journal.pone.0151607.t002

###### Quality assessment.

![](pone.0151607.t002){#pone.0151607.t002g}

  Study                                              Is the case definition adequate?   Representativeness of the cases   Selection of Controls   Definition of Controls   Comparability of cases and controls on the basis of the design or analysis   Ascertainment of exposure   Same method of ascertainment for cases and controls   Non-Response rate
  -------------------------------------------------- ---------------------------------- --------------------------------- ----------------------- ------------------------ ---------------------------------------------------------------------------- --------------------------- ----------------------------------------------------- -------------------
  **Ashjazadeh**\[[@pone.0151607.ref016]\]           \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Ben Salem-Berrabah**\[[@pone.0151607.ref014]\]   \*                                 \*                                                                                                                                                              \*                          \*                                                    \*
  **Bombeli**\[[@pone.0151607.ref011]\]              \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Boncoraglio**\[[@pone.0151607.ref017]\]          \*                                 \*                                                                                                                                                              \*                          \*                                                    \*
  **Colaizo**\[[@pone.0151607.ref029]\]              \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Gadelha**\[[@pone.0151607.ref018]\]              \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Hillier**\[[@pone.0151607.ref012]\]              \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Koopman**\[[@pone.0151607.ref030]\]              \*                                 \*                                                                                                                                                              \*                          \*                                                    \*
  **Le Cam-Duchez**\[[@pone.0151607.ref019]\]        \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Lichy**\[[@pone.0151607.ref020]\]                \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Madonna**\[[@pone.0151607.ref021]\]              \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Martinelli** \[[@pone.0151607.ref031]\]          \*                                 \*                                \*                                                                                                                            \*                          \*                                                    \*
  **Nagaraja**\[[@pone.0151607.ref032]\]             \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Rahimi**\[[@pone.0151607.ref023]\]               \*                                 \*                                                                                                                                                              \*                          \*                                                    \*
  **Reuner**\[[@pone.0151607.ref010]\]               \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Ringelstein**\[[@pone.0151607.ref024]\]          \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Rodrigues**\[[@pone.0151607.ref025]\]            \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*
  **Ventura**\[[@pone.0151607.ref027]\]              \*                                                                   \*                                                                                                                            \*                          \*                                                    \*
  **Voetsch**\[[@pone.0151607.ref028]\]              \*                                 \*                                \*                      \*                                                                                                    \*                          \*                                                    \*

![Flow diagram.](pone.0151607.g001){#pone.0151607.g001}

In total the 19 studies evaluated 868 cases of cerebral venous thrombosis and 3999 controls (see [Table 3](#pone.0151607.t003){ref-type="table"} for a more comprehensive review of the number of patients included in each study individual OR and bias assessment). Prothrombin G20210A was found in 103/868 of the patients with cerebral venous thrombosis and 105/3999 of the controls \[random effects pooled OR 5.838, 95% CI 3.96 to 8.58; I^2^17.9%\] ([Fig 2](#pone.0151607.g002){ref-type="fig"}) with low evidence of bias (Figs [3](#pone.0151607.g003){ref-type="fig"} and [4](#pone.0151607.g004){ref-type="fig"}). As shown in [Table 3](#pone.0151607.t003){ref-type="table"} the addition of the two relevant studies not reporting the diagnostic methods used did not modify the random effects pooled OR\[[@pone.0151607.ref013],[@pone.0151607.ref026]\].

10.1371/journal.pone.0151607.t003

###### Meta-analysis and individual study data.

![](pone.0151607.t003){#pone.0151607.t003g}

  ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------- ---------------- -------------------
  **Study**                                                                          **Carriers of PTGM**[\^](#t003fn001){ref-type="table-fn"}**/CVT**[\*](#t003fn002){ref-type="table-fn"} **cases**   **Carriers of PTGM**[\^](#t003fn001){ref-type="table-fn"}**/Healthy controls**   **Odds ratio**   **95% CI**
  Ashjazadeh                                                                         2/57                                                                                                               2/50                                                                             0.87             0.11 to 6.43
  Ben Salem-Berrabah                                                                 0/26                                                                                                               5/197                                                                            0.66             0.035 to 12.28
  Bombeli                                                                            2/28                                                                                                               2/80                                                                             3.00             0.40 to 22.38
  Boncoraglio                                                                        3/26                                                                                                               3/100                                                                            4.21             0.79 to 22.26
  Colaizo                                                                            8/45                                                                                                               9/286                                                                            6.65             2.41 to 18.31
  Gadelha                                                                            5/31                                                                                                               2/217                                                                            20.67            3.81 to 111.99
  Hillier                                                                            0/15                                                                                                               4/300                                                                            2.12             0.10 to 41.26
  Koopman                                                                            1/19                                                                                                               0/19                                                                             3.16             0.12 to 82.64
  Le Cam-Duchez                                                                      7/26                                                                                                               3/84                                                                             9.94             2.35 to 42.063
  Lichy                                                                              8/77                                                                                                               5/202                                                                            4.56             1.44 to 14.43
  Madona                                                                             5/10                                                                                                               16/259                                                                           15.18            3.98to 57.93
  Martinelli                                                                         26/121                                                                                                             5/242                                                                            12.97            4.83 to 34.78
  Nagaraja                                                                           0/96                                                                                                               0/103                                                                            \-               
  Rahimi                                                                             0/24                                                                                                               1/100                                                                            1.35             0.053 to 34.25
  Reuner                                                                             4/45                                                                                                               8/354                                                                            4.22             1.21 to 14.62
  Ringelstein                                                                        14/136                                                                                                             33/1007                                                                          3.38             1.76 to 6.50
  Rodrigues                                                                          7/42                                                                                                               1/134                                                                            26.60            3.167 to 223.42
  Ventura                                                                            9/30                                                                                                               1/40                                                                             16.71            1.98 to 141.07
  Voetsch                                                                            2/14                                                                                                               5/225                                                                            7.33             1.28 to 41.77
  **Total (random effects)**                                                         **103/868**                                                                                                        **105/3999**                                                                     **5.83**         **3.96 to 8.58**
  **I**^**2**^ **(inconsistency)**                                                                                                                                                                                                                                                       17.9%            **0.00 to 53.41**
  Bias indicators. Harbold-Egger: bias = -0.30 (92.5% CI = -2.05 to 1.46) P = 0.74                                                                                                                                                                                                                        
  **Analysis with excluded studies**                                                 **Carriers of PTGM**[\^](#t003fn001){ref-type="table-fn"}**/CVT**[\*](#t003fn002){ref-type="table-fn"} **cases**   **Carriers of PTGM**[\^](#t003fn001){ref-type="table-fn"}**/Healthy controls**   **Odds ratio**   **95% CI**
  Margaglione                                                                        6/28                                                                                                               56/1301                                                                          6.06             2.36 to 15.54
  Tufano                                                                             16/55                                                                                                              10/183                                                                           7.09             2.99 to 16.82
  **Total (random effects)**                                                         125/951                                                                                                            171/5483                                                                         5.93             4.32 to 8.13
  **I**^**2**^ **(inconsistency)**                                                                                                                                                                                                                                                       8.09%%           **0.00 to 43.53**
  Bias indicators. Harbold-Egger: bias = -0.21 (92.5% CI = -1.83to 1.41) P = 0.80                                                                                                                                                                                                                         
  ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------- ---------------- -------------------

\^PTGM: prothrombin G20210A;

\*CVT: cerebral vein thrombosis

![Forest plot prevalence of prothrombin G20210A.](pone.0151607.g002){#pone.0151607.g002}

![Bias assessment plot.](pone.0151607.g003){#pone.0151607.g003}

![L'Abbé bias plot.](pone.0151607.g004){#pone.0151607.g004}

As shown in [Table 4](#pone.0151607.t004){ref-type="table"}, in Italian studies \[[@pone.0151607.ref017],[@pone.0151607.ref021],[@pone.0151607.ref027],[@pone.0151607.ref029],[@pone.0151607.ref031]\] prothrombin G20210A was found in 51/232 of patients with cerebral venous thrombosis and in 34/927 of the controls (random effects pooled OR 9.69, 95% 5.51 to 17.05; I^2^ 0%). In Brazilian studies\[[@pone.0151607.ref018],[@pone.0151607.ref025],[@pone.0151607.ref028]\] prothrombin G20210A was found in 14/82 of patients with cerebral venous thrombosis and in 14/576 of the controls (random effects pooled OR 7.02, 95% CI 2.79 to 17.63; I^2^ 21.8%). In the three German\[[@pone.0151607.ref010],[@pone.0151607.ref020],[@pone.0151607.ref024]\] studies prothrombin G20210A was found in 28/255 of patients with cerebral venous thrombosis and in 49/1563 of the controls (random effects pooled OR 3.77, 95% CI 2.22 to 6.26; I^2^ 0%). In the two Iranian studies\[[@pone.0151607.ref016],[@pone.0151607.ref023]\] there was no difference in the prevalence prothrombin G20210A between patients with cerebral venous thrombosis and controls (random effects pooled OR 0.98, 95% CI 0.18 to 5.39; I^2^ 0%).

10.1371/journal.pone.0151607.t004

###### Individual country meta-analysis.

![](pone.0151607.t004){#pone.0151607.t004g}

  ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------- ---------------- -------------------
  **Study**                                                                          **Carriers of PTGM**[\^](#t004fn001){ref-type="table-fn"}**/CVT**[\*](#t004fn002){ref-type="table-fn"} **cases**   **Carriers of PTGM**[\^](#t004fn001){ref-type="table-fn"}**/Healthy controls**   **Odds ratio**   **95% CI**
  **Italy**                                                                                                                                                                                                                                                                                               
  Boncoraglio                                                                        3/26                                                                                                               3/100                                                                            4.21             0.79 to 22.26
  Colaizzo                                                                           8/45                                                                                                               9/286                                                                            6.65             2.41 to 18.31
  Madona                                                                             5/10                                                                                                               16/259                                                                           15.18            3.98 to 57.93
  Martinelli                                                                         26/121                                                                                                             5/242                                                                            12.97            4.83 to 34.78
  Ventura                                                                            9/30                                                                                                               1/40                                                                             16.71            1.98 to 141.07
  **Total (random effects)**                                                         **51/232**                                                                                                         **34/927**                                                                       **9.69**         **5.51 to 17.05**
  **I**^**2**^ **(inconsistency)**                                                                                                                                                                                                                                                       **0.00%**        **0.00 to 64.1**
  Bias indicator. Horbold-Egger: bias = 1.8 (92.5% CI = -2.96to 6.63) P = 0.38                                                                                                                                                                                                                            
  **Brazil**                                                                                                                                                                                                                                                                                              
  Gadelha                                                                            5/26                                                                                                               5/217                                                                            10.0             2.70 to 37.72
  Rodrigues                                                                          7/42                                                                                                               7/134                                                                            3.62             1.19 to 11.03
  Voetsch                                                                            2/14                                                                                                               2/225                                                                            18.58            2.40 to 143.52
  **Total (random effects)**                                                         **14/82**                                                                                                          **14/576**                                                                       **7.02**         **2.79 to 17.63**
  **I**^**2**^ **(inconsistency)**                                                                                                                                                                                                                                                       **22.82%**       **0.00 to 97.41**
  Bias indicator. Horbold-Egger: bias = 1.37 (92.5% CI = -20.93 to 23.68) P = 0.69                                                                                                                                                                                                                        
  **Germany**                                                                        **Carriers of PTGM**[\^](#t004fn001){ref-type="table-fn"}**/CVT**[\*](#t004fn002){ref-type="table-fn"} **cases**   **Carriers of PTGM**[\^](#t004fn001){ref-type="table-fn"}**/Healthy controls**                    
  Lichy                                                                              10/77                                                                                                              5/202                                                                            5.88             1.94 to 17.82
  Reuner                                                                             4/45                                                                                                               8/354                                                                            4.22             1.21 to 14.62
  Ringelstein                                                                        14/136                                                                                                             33/1007                                                                          3.38             1.76 to 6.50
  **Total (random effects)**                                                         **28/255**                                                                                                         **49/1563**                                                                      **3.77**         **2.22 to 6.26**
  **I**^**2**^ **(inconsistency)**                                                                                                                                                                                                                                                       **0.00%**        **0.00 to 72.29**
  Bias indicators. Horbold-Egger: bias = 0.93 (92.5% CI = -3.34 to 5.21) P = 0.31                                                                                                                                                                                                                         
  **Iran**                                                                           **Carriers of PTGM**[\^](#t004fn001){ref-type="table-fn"}**/CVT**[\*](#t004fn002){ref-type="table-fn"} **cases**   **Carriers of PTGM**[\^](#t004fn001){ref-type="table-fn"}**/Healthy controls**                    
  Ashjazadeh                                                                         2/57                                                                                                               2/50                                                                             0.87             0.11 to 6.43
  Rahimi                                                                             0/24                                                                                                               1/100                                                                            1.35             0.05 to 34.25
  **Total (random effects)**                                                         **2/81**                                                                                                           **3/150**                                                                        **0.98**         **0.18 to 5.39**
  **I**^**2**^ **(inconsistency)**                                                                                                                                                                                                                                                       **0.00%**        **0.00 to 0.00**
  Bias indicators not done due to low number of studies                                                                                                                                                                                                                                                   
  ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------- ---------------- -------------------

\^PTGM: prothrombin G20210A;

\*CVT: cerebral vein thrombosis

Discussion {#sec013}
==========

Our systematic review confirmed a significant association of prothrombin G20210A with cerebral venous thrombosis but this association is highly dependent to the country of origin. Individual country meta-analysis suggested significant association between prothrombin G20210A and cerebral venous thrombosis in studies conducted in Italy\[[@pone.0151607.ref017],[@pone.0151607.ref021],[@pone.0151607.ref027],[@pone.0151607.ref031]\], Brazil\[[@pone.0151607.ref018],[@pone.0151607.ref025],[@pone.0151607.ref028]\] and Germany\[[@pone.0151607.ref010],[@pone.0151607.ref020],[@pone.0151607.ref024]\]. Consistently with prior literature\[[@pone.0151607.ref003]\] suggesting a low prevalence of the condition in those from Asian or African descent, none of the studies included from India\[[@pone.0151607.ref033]\], Iran\[[@pone.0151607.ref016],[@pone.0151607.ref023]\] or Tunisia\[[@pone.0151607.ref014]\]reported an association between prothrombin G20210A and cerebral venous thrombosis. For the first time, and to the best of our knowledge, information about the geographical variations of prothrombin G20210A with cerebral venous thrombosis has been presented.

Similar to deep vein thrombosis and pulmonary embolism the question that remains unanswered is the value of screening for prothrombin G20210A with cerebral venous thrombosis in order to predict who is at high risk of recurrent venous thromboembolism? Our results would suggest that given it high prevalence in countries such as Italy or Brazil, it would be reasonable to screen for this condition, especially in those with unprovoked events\[[@pone.0151607.ref034]\]. On the other hand, evidence suggests that the rate of recurrent venous thromboembolism associated with prothrombin G20210A gene mutation is low in those with deep vein thrombosis or pulmonary embolism\[[@pone.0151607.ref035],[@pone.0151607.ref036]\]. Two our knowledge only two studies, conducted in Italy, have reported the rate of recurrent venous thromboembolism in patients with prothrombin G20210A and cerebral venous thrombosis who discontinue anticoagulation\[[@pone.0151607.ref026],[@pone.0151607.ref037]\], none of them showed an increased risk for recurrent venous thromboembolism in carriers of prothrombin G20210A diagnosed with cerebral venous thrombosis.

Other systematic reviews have addressed the prevalence of prothrombin G20210A in patients diagnosed with cerebral venous thrombosis\[[@pone.0151607.ref002],[@pone.0151607.ref038]\]. Our results confirms prior findings in other systematic reviews\[[@pone.0151607.ref002],[@pone.0151607.ref038]\] suggesting a significant association between prothrombin G20210A diagnosed with cerebral venous thrombosis and provide. Also for the first time information about geographical variations associated with the prevalence of prothrombin G20210A in patients with cerebral vein thrombosis is presented. As previously suggested in patients with deep vein thrombosis or pulmonary embolism\[[@pone.0151607.ref003]--[@pone.0151607.ref007]\], we found that the prevalence of prothrombin gene mutation was higher in southern European countries, and no association in Asian countries.

Our systematic review has limitations. First, we did could not evaluate the prevalence of prothrombin gene mutation in patients with unprovoked cerebral venous thrombosis. Second, not all the studies used matching and, as such, potentially introduced bias. Third, homozygous prothrombin G20210A could not be assessed owing to the small number of patients affected. Fourth, our individual country analysis did not take into different genetic populations who might live in a country\[[@pone.0151607.ref039]\]. Fifth, we did not adjust for important risk factors (such as provoked cerebral vein thrombosis vs. unprovoked; female vs. male) which could introduce some bias. Finally, most of the studies included did not reported on the Hardy-Weinberg equilibrium and given that only two of the studies reported on it we did not conducted a sensitivity analysis\[[@pone.0151607.ref040],[@pone.0151607.ref041]\].

In conclusion, our systematic review confirmed a significant association of prothrombin G20210A with cerebral venous thrombosis but suggest that this association is highly dependent to the country of origin. More studies should evaluate the role of prothrombin G20210A as a predictor of recurrent venous thromboembolism in patients with cerebral venous thrombosis, especially in those countries where its prevalence high prevalence.
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